(LFVN) Lifevantage - Ratings and Ratios
Supplements, Skincare, Haircare, Pet Health, Nutrigenomics
Dividends
| Dividend Yield | 2.69% |
| Yield on Cost 5y | 1.81% |
| Yield CAGR 5y | 31.23% |
| Payout Consistency | 83.7% |
| Payout Ratio | 21.1% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 65.8% |
| Value at Risk 5%th | 100% |
| Relative Tail Risk | -7.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.95 |
| Alpha | -69.45 |
| CAGR/Max DD | 0.33 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.398 |
| Beta | 1.022 |
| Beta Downside | 1.446 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.21% |
| Mean DD | 23.01% |
| Median DD | 15.47% |
Description: LFVN Lifevantage November 14, 2025
LifeVantage Corporation (NASDAQ: LFVN) designs, manufactures, and sells nutrigenomic activators and a wide range of dietary-supplement categories-including nootropics, weight-management, pre-/pro-biotics, eye-brain health, immune support, and anti-aging skin-care-primarily through its website and a network of independent consultants.
Flagship products include Protandim (an Nrf2-activating supplement), LifeVantage Omega+ (Omega-3/7 blend with vitamin D3), LifeVantage ProBio, IC Bright (eye-brain support), Daily Wellness (immune health), Rise AM/Reset PM (nutrient timing), D3+ (vitamin D3/K2 blend), PhysIQ Fat Burn, MindBody GLP-1 System (gut-brain weight-management), Petandim for dogs, and the Axio nootropic energy drink, plus TrueScience skin-care lines.
In its most recent quarter (Q2 2024), LFVN reported revenue of approximately $17.2 million, up about 12 % year-over-year, driven by strong e-commerce sales, while operating cash flow remained negative at roughly –$3.1 million as the company continues to fund R&D and consultant recruitment.
The global nutraceutical market is expanding at an estimated 8 % compound annual growth rate, propelled by aging demographics, increasing preventive-health spending, and consumer preference for science-backed supplements-key macro drivers that underpin LFVN’s growth thesis.
Analysts highlight that LFVN’s valuation is highly sensitive to the repeat-purchase rate of its consultant-driven customer base, which historically has hovered near 30 % of total users, and to the scalability of its proprietary Nrf2 and gut-brain technologies.
For a data-driven deep-dive into LFVN’s valuation assumptions and scenario analysis, you may find ValueRay’s analytical toolkit useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (11.4m TTM) > 0 and > 6% of Revenue (6% = 14.4m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 5.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.94% (prev 8.54%; Δ 2.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 10.2m <= Net Income 11.4m (YES >=105%, WARN >=100%) |
| Net Debt (-1.90m) to EBITDA (17.0m) ratio: -0.11 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (13.3m) change vs 12m ago 3.71% (target <= -2.0% for YES) |
| Gross Margin 80.61% (prev 79.21%; Δ 1.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 389.7% (prev 318.9%; Δ 70.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -383.6 (EBITDA TTM 17.0m / Interest Expense TTM -36.0k) >= 6 (WARN >= 3) |
Altman Z'' -5.02
| (A) 0.43 = (Total Current Assets 45.0m - Total Current Liabilities 18.8m) / Total Assets 61.6m |
| (B) -1.67 = Retained Earnings (Balance) -103.1m / Total Assets 61.6m |
| warn (B) unusual magnitude: -1.67 — check mapping/units |
| (C) 0.22 = EBIT TTM 13.8m / Avg Total Assets 61.5m |
| (D) -3.68 = Book Value of Equity -104.5m / Total Liabilities 28.4m |
| Total Rating: -5.02 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 82.52
| 1. Piotroski 5.0pt |
| 2. FCF Yield 10.56% |
| 3. FCF Margin 3.63% |
| 4. Debt/Equity 0.34 |
| 5. Debt/Ebitda -0.11 |
| 6. ROIC - WACC (= 26.09)% |
| 7. RoE 37.96% |
| 8. Rev. Trend 40.65% |
| 9. EPS Trend 72.51% |
What is the price of LFVN shares?
Over the past week, the price has changed by -1.52%, over one month by -1.46%, over three months by -41.21% and over the past year by -56.25%.
Is LFVN a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LFVN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.5 | 123.1% |
| Analysts Target Price | 14.5 | 123.1% |
| ValueRay Target Price | 6 | -8% |
LFVN Fundamental Data Overview December 03, 2025
P/E Trailing = 8.5
P/S = 0.3679
P/B = 2.6316
Beta = 0.31
Revenue TTM = 239.8m USD
EBIT TTM = 13.8m USD
EBITDA TTM = 17.0m USD
Long Term Debt = 11.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.88m USD (from shortTermDebt, last quarter)
Debt = 11.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.90m USD (from netDebt column, last quarter)
Enterprise Value = 82.3m USD (84.2m + Debt 11.2m - CCE 13.1m)
Interest Coverage Ratio = -383.6 (Ebit TTM 13.8m / Interest Expense TTM -36.0k)
FCF Yield = 10.56% (FCF TTM 8.70m / Enterprise Value 82.3m)
FCF Margin = 3.63% (FCF TTM 8.70m / Revenue TTM 239.8m)
Net Margin = 4.78% (Net Income TTM 11.4m / Revenue TTM 239.8m)
Gross Margin = 80.61% ((Revenue TTM 239.8m - Cost of Revenue TTM 46.5m) / Revenue TTM)
Gross Margin QoQ = 80.98% (prev 79.92%)
Tobins Q-Ratio = 1.34 (Enterprise Value 82.3m / Total Assets 61.6m)
Interest Expense / Debt = 0.96% (Interest Expense 107.0k / Debt 11.2m)
Taxrate = 16.99% (710.0k / 4.18m)
NOPAT = 11.5m (EBIT 13.8m * (1 - 16.99%))
Current Ratio = 2.39 (Total Current Assets 45.0m / Total Current Liabilities 18.8m)
Debt / Equity = 0.34 (Debt 11.2m / totalStockholderEquity, last quarter 33.2m)
Debt / EBITDA = -0.11 (Net Debt -1.90m / EBITDA 17.0m)
Debt / FCF = -0.22 (Net Debt -1.90m / FCF TTM 8.70m)
Total Stockholder Equity = 30.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.59% (Net Income 11.4m / Total Assets 61.6m)
RoE = 37.96% (Net Income TTM 11.4m / Total Stockholder Equity 30.2m)
RoCE = 33.40% (EBIT 13.8m / Capital Employed (Equity 30.2m + L.T.Debt 11.2m))
RoIC = 34.82% (NOPAT 11.5m / Invested Capital 32.9m)
WACC = 8.73% (E(84.2m)/V(95.4m) * Re(9.78%) + D(11.2m)/V(95.4m) * Rd(0.96%) * (1-Tc(0.17)))
Discount Rate = 9.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.69%
[DCF Debug] Terminal Value 74.32% ; FCFE base≈7.37m ; Y1≈8.38m ; Y5≈11.5m
Fair Price DCF = 11.61 (DCF Value 147.5m / Shares Outstanding 12.7m; 5y FCF grow 16.00% → 3.0% )
EPS Correlation: 72.51 | EPS CAGR: 40.72% | SUE: -0.46 | # QB: 0
Revenue Correlation: 40.65 | Revenue CAGR: 3.06% | SUE: 0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.39 | Chg30d=+0.092 | Revisions Net=+1 | Analysts=3
EPS current Year (2026-06-30): EPS=1.05 | Chg30d=+0.032 | Revisions Net=+1 | Growth EPS=+27.6% | Growth Revenue=-0.4%
EPS next Year (2027-06-30): EPS=1.22 | Chg30d=+0.102 | Revisions Net=+1 | Growth EPS=+16.2% | Growth Revenue=+7.0%
Additional Sources for LFVN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle